Emerging studies on retatrutide, a dual activator for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, indicate significant outcomes in addressing excess body fat and type 2 glucose intolerance. Early data from clinical experiments reveal notable decreases in body weight and improved glucose control. Ongoing examination is